Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2007

View Archived Issues

Immune responses, clinical benefit seen with T-cell vaccination in rheumatoid arthritis

Novel therapeutic agents for respiratory disorders disclosed in recent patent literature

Recent patents describe novel agents for anxiety, depression, psychosis etc.

Novel treatment options for thrombotic disorders reported in recent patents

Phase II results suggest tetomilast is active in ulcerative colitis

Statins linked to lower risk of infection-related mortality

5-HT4 activation inhibits Abeta secretion and increases survival of neurons oversecreting Abeta

Pharmacopeia and Organon establish new alliance

VASTox signs chemical genomics agreements

RotaTeq prescribing information updated

Effect of rifalazil investigated on atherosclerotic changes in the carotid artery

Smallpox drug SIGA-246 studied in phase I trial

Agreement to study FavId with Leukine in B-cell NHL

Sanofi pasteur licenses ChimeriVax-JE vaccine from Acambis

FDA extends review of rimonabant

Phase I study under way for DARA compound PS-433540

AndroScience files IND for ASC-J9 for acne

Tikvah Therapeutics licenses compounds for anxiety-related disorders

BrainStorm's adult stem cell technology studied in Parkinson's disease in primates

Treatment under way in phase II study of Litx therapy in glioma

Completion of phase III studies for Metvix with Aktilite

IPI-504 studied for NSCLC

Teverelix LA has same effect on testosterone suppression in normal and obese subjects

Bavituximab shows signs of dose dependent antiviral activity in chronic HCV

FDA accepts for review two sNDAs for Januvia

Roche files for Tamiflu 30 and 45 mg capsules in Europe

Satraplatin NDA filing completed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.